Other substances

Cetirizine

A histamin H1-receptor antagonist.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

General information

Cetirizine Hydrochloride is a synthetic histamine H1-receptor antagonist. It is used for relief of symptoms of seasonal or perennial allergic rhinitis and of chronic urticaria (NCIt).

Cetirizine on DrugBank
Cetirizine on PubChem
Cetirizine on Wikipedia


Marketed as

ALERLISIN; CETRYN; CETIRIZINE (HYDROCHLORIDE); FORMISTIN; HITRIZIN; QUZYTTIR; VIRLIX; ZIRTEK; ZYRTEK; ZYRLEX

 

Structure image - Cetirizine

C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients
Severe severity Small molecule Critical severity Cohort study 		Patients 2.68

In combination with famotidine reduced progression in symptom severity. Sample size: 110. Dosage: 10 mg twice daily. Endpoints: Increase in the rate of discharge; reduction in ventilation requirements; reduction in inpatient mortality rate; reduction in duration of hospitalization.


 Aug/29/2020

AI-suggested references

Link Publication date
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients
Jan/16/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04836806 Cetirizine and Famotidine for COVID-19 Withdrawn Phase 4 Aug/01/2021 Jul/01/2022
  • Alternative id - STUDY00001722
  • Interventions - Drug: Cetirizine and Famotidine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Emory University Hospital at Wesley Woods COVID-19 Testing Facility, Atlanta, Georgia, United States|Emory Healthcare Network Peachtree Immediate Care COVID-19 Testing Centers, Atlanta, Georgia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to resolution of symptoms|Severity of Symptoms|Time to Resolution of Individual Symptoms|Incidence of Hospitalization|Incidence of Intensive Care Unit (ICU) Admission|Incidence of Death
Export (.csv)